New Drug Delivery Technology Developed by Mercury Bio
The New Mexico biotech company Mercury Bio, formerly Spartina Biotechnologies, has developed a new patent-pending technology that will facilitate the delivery of both RNA therapeutics, and small-molecule drugs, to diseased cells that have been targeted.
Due to the use of RNA in COVID vaccines, scientists are doing more research on RNA therapeutics to not just protect from diseases, but to cure diseases. The biggest challenge is being able to deliver RNA therapeutics to the exact cells where they are needed to affect the genes responsible for a particular disease.
Also, many small-molecule pharmaceutical drugs currently on the market are impaired by off-target delivery. This can lead to negative side effects and low bioavailability. Small-molecule drugs are also often destroyed or eliminated by the body before they even have a chance to deliver treatment.
Both of these things lead to a problem of ineffective drug delivery.
Mercury Bio has developed a biomolecular, advanced drug delivery system called ADDS™. This new system has been created to reduce the barriers that RNA therapeutics come up against in vivo. This is done by engineering naturally occurring vesicles to encapsulate RNA therapeutics and small-molecule drugs, and by modifying these vesicles to display a cell-specific targeting mechanism.
To learn more about how advanced drug delivery systems can impact the potency of next-generation pharmaceuticals, visit www.mercurybio.com
To learn more see the entire article at: Mercury Bio Develops New Biomolecular Drug Delivery Platform
Mercury Bio is supported by the New Mexico Consortium.